Back to home

Clinical research

Clinical studies.

The evidence behind personalised microbiome modulation — in inflammatory bowel disease and oncology supportive care. Read the publications, not just the headline results.

4

Publications linked on the source page

1,200+

Participants in documented clinical studies, reported by NostraBiome

The programme-wide participant count is not the combined sample size of these four papers. Study cohorts may overlap; do not add them together or assume independent validation.

NostraBiome’s research source
Reviewing health measurements in a clinical setting

01 · Adult inflammatory bowel disease

Biomedicines · 2025

Introducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease

Results from NostraBiome’s Internal Validation Study

Read full study

DOI: 10.3390/biomedicines13040795

Population & design
Patients with inflammatory bowel disease; internal validation study.
What was studied
Personalised microbiome modulation informed by microbiome and clinical data, evaluated for symptom control and remission-related outcomes.
Reported findings & interpretation
The source describes improvements in symptoms and remission-related measures. Endpoint definitions and the analysis should be reviewed in the full publication.

02 · Paediatric inflammatory bowel disease

Microorganisms · 2025

Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease

A Multi-Omics and Interventional Approach

Read full study

DOI: 10.3390/microorganisms13051047

Population & design
Children with inflammatory bowel disease.
What was studied
Multi-omic analysis combining metagenomics, metabolomics, transcriptomics and clinical biomarkers to inform microbiome-targeted interventions.
Reported findings & interpretation
The study examines dysbiosis, intervention targets and clinical response in paediatric IBD. Its findings should not be generalised to all childhood digestive conditions.

03 · Treatment-refractory inflammatory bowel disease

International Journal of Molecular Sciences

AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD

A Real-World Study

Read full study

DOI: 10.3390/ijms27010201

Population & design
358 adults with treatment-refractory IBD · three-month programme, as summarised by NostraBiome.
What was studied
Stool metagenomics, blood biomarkers, micronutrient panels and clinical information informed individualised dietary and microbiome-modulation plans.
Reported findings & interpretation
NostraBiome reports over 70% describing their overall condition as ‘much improved’ at three months, and reductions in hs-CRP and faecal calprotectin in over 85% of cases. This is the proportion showing reductions, not an 85% reduction in marker levels.

04 · Oncology supportive care

Cancers

AI-Guided Personalized Gut Microbiome Modulation for Persistent Secondary Gastrointestinal Symptoms in Oncology Patients

Clinical Efficacy and Biological Correlates from a Prospective Validation Study

Read full study

DOI: 10.3390/cancers18091453

Population & design
Oncology patients with persistent secondary gastrointestinal symptoms; prospective validation study.
What was studied
Microbiome, clinical and laboratory data informed personalised dietary and supplement recommendations, evaluated over three months.
Reported findings & interpretation
The source describes improved bowel habits and energy, alongside changes in beneficial gut bacteria and metabolic markers. This is supportive-care research, not evidence of treating cancer or improving survival.

Evidence in context

What these studies can — and cannot — tell us.

Real-world and internal validation results can identify promising clinical signals. Without a suitable randomised comparator, changes cannot be attributed to the intervention alone: concurrent therapy, selection, reporting and other confounders matter.

The interventions combine several elements. Outcomes do not isolate the effect of AI, a supplement or an individual app feature. Findings in a defined IBD or oncology cohort do not establish efficacy in menopause, aging or every metabolic condition.

These summaries follow NostraBiome’s source page. Consult each publication for eligibility, sample size, endpoints, adverse events, conflicts of interest and full limitations.

Medical-device status is separate from clinical evidence.

NostraBiome describes its software as CE-marked under EU MDR 2017/745, with ISO 13485 quality management and EUDAMED registration. CE marking is a conformity status; it is not a guarantee of clinical benefit for every use. Diagnosis and treatment decisions remain with the treating clinician.

The science behind the modelsFor doctors & clinics